- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03912194
Early Withdrawal Exposure and Negative Affect Withdrawal (NAW) Regulation Training for Smoking Cessation
December 7, 2023 updated by: Peter Hendricks, University of Alabama at Birmingham
Smoking remains the single most preventable cause of morbidity and mortality in the United States, accounting for approximately half a million deaths every year.
The current study will investigate the efficacy and mechanisms of change of a novel smoking cessation intervention.
The current study will thus provide essential information regarding a treatment that has the potential to enhance the efficacy of existing smoking cessation interventions, thereby having a beneficial impact on the public health of the United States.
Study Overview
Status
Recruiting
Conditions
Detailed Description
Cigarette smoking remains the single most preventable cause of mortality and morbidity in the United States.
Long-term abstinence rates for even the most rigorous of smoking cessation treatments range between 20% and 35%.
It is therefore essential that research continue to investigate novel smoking cessation interventions.
Leading contemporary theories of addiction motivation posit that the escape or avoidance of negative affect withdrawal (NAW) symptoms (e.g., anger, anxiety, and depression/sadness) constitutes a strong motivational basis for cigarette smoking and plays a critical role in relapse to cigarette use.
However, whereas NAW symptoms appear to exert a powerful influence on smoking cessation treatment outcome, smoking cessation interventions may exert only modest effects on NAW symptoms.
Accordingly, it has been proposed that smoking cessation interventions may be augmented by aiding smokers in the practice of NAW regulation strategies.
The primary goal of this investigation is to evaluate an early withdrawal exposure plus NAW regulation training intervention for smoking cessation.
Specific aims include evaluating the efficacy of the treatment components and investigating potential mediators and moderators of the treatment components.
Participants will be adult smokers (N = 400) of at least 5 cigarettes per day with the intention to quit smoking.
Using a factorial design, participants will be randomized to early withdrawal exposure (yes vs. no) and behavioral intervention (NAW regulation training vs. relaxation control training), resulting in four distinct conditions.
The investigator's primary hypothesis is that early withdrawal exposure plus NAW regulation training will produce higher rates of seven-day point-prevalence abstinence at 1, 3, and 6 months after end-of-treatment, suggesting a synergistic (i.e., non-additive) effect of the two intervention components.
Mediators (e.g., in-session withdrawal symptoms) and moderators (e.g., demographic characteristics, tobacco dependence) will be investigated via established analyses.
These data will advance the experimental intervention with a focus on targeting mechanisms of change as well as participant characteristics to which the intervention may be tailored.
The experimental intervention described in the current proposal has the potential to ultimately enhance the efficacy of existing smoking cessation interventions and will therefore contribute uniquely to the field.
Study Type
Interventional
Enrollment (Estimated)
400
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35294
- Recruiting
- Ryals Public Health Building
-
Contact:
- Peter S Hendricks, PhD
- Phone Number: 205-202-1387
- Email: phendricks@uab.edu
-
Principal Investigator:
- Peter S Hendricks, PhD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- at least 18 years of age
- smoke at least 5 cigarettes per day
- Expired breath carbon monoxide (CO) reading of at least five parts per million
- report the intention to quit
- reside in the Birmingham area with no plan to relocate outside of the area in the next 6 months
- access to a telephone
Exclusion Criteria:
- inability to speak English
- presence of a condition that contraindicates use of the nicotine patch
- presence of conditions that might interfere with compliance with the protocol or greatly complicate treatment
- any acutely life-threatening disease
- concurrent participation in a formal treatment program for smoking cessation
- current use of any pharmacotherapy for smoking cessation
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Factorial Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Early Withdrawal Exposure plus NAW Regulation Training
The development, application, modification, and repeated practice of individualized withdrawal regulation strategies (e.g., behavioral and cognitive strategies for allaying withdrawal symptoms) across the first 4 hours of abstinence over 4 separate sessions.
|
Participants will generate and refine individualized withdrawal regulation strategies with the aid of a therapist
Exposure to the first 4 hours of abstinence across 4 separate sessions
|
Active Comparator: Early Withdrawal Exposure plus Relaxation Control Training
The development, application, modification, and repeated practice of relaxation strategies across the first 4 hours of abstinence over 4 separate sessions.
|
Exposure to the first 4 hours of abstinence across 4 separate sessions
Participants will generate and refine relaxation techniques with the aid of a therapist
|
Active Comparator: NAW Regulation Training Only
The development, application, modification, and repeated practice of individualized withdrawal regulation strategies (e.g., behavioral and cognitive strategies for allaying withdrawal symptoms) over 4 separate sessions involving smoking as usual.
|
Participants will generate and refine individualized withdrawal regulation strategies with the aid of a therapist
|
Active Comparator: Relaxation Control Training Only
The development, application, modification, and repeated practice of relaxation strategies over 4 separate sessions involving smoking as usual.
|
Participants will generate and refine relaxation techniques with the aid of a therapist
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Smoking cessation as evaluated by self-reported, biochemically-confirmed seven-day point-prevalence abstinence
Time Frame: 1 month after end-of-treatment
|
Self reported abstinence from smoking ("no smoking, not even a puff) in the past seven days, biochemically confirmed by a breath carbon monoxide reading of 3 or less
|
1 month after end-of-treatment
|
Smoking cessation as evaluated by self-reported, biochemically-confirmed seven-day point-prevalence abstinence
Time Frame: 3 months after end-of-treatment
|
Self reported abstinence from smoking ("no smoking, not even a puff) in the past seven days, biochemically confirmed by a breath carbon monoxide reading of 3 or less
|
3 months after end-of-treatment
|
Smoking cessation as evaluated by self-reported, biochemically-confirmed seven-day point-prevalence abstinence
Time Frame: 6 months after end-of-treatment
|
Self reported abstinence from smoking ("no smoking, not even a puff) in the past seven days, biochemically confirmed by a breath carbon monoxide reading of 3 or less
|
6 months after end-of-treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cessation milestones as determined by the Timeline Followback Interview
Time Frame: 1 month after end-of-treatment
|
1) Was initial abstinence achieved (was there any day of non-smoking within the first two weeks after the quit date; yes or no)?; 2) latency to lapse (number of days to the first cigarette after the quit day); 3) was there a progression from lapse to relapse (defined as seven consecutive days of smoking; yes or no)?
|
1 month after end-of-treatment
|
Cessation milestones as determined by the Timeline Followback Interview
Time Frame: 3 months after end-of-treatment
|
1) latency to lapse (number of days to the first cigarette after the quit day); 2) was there a progression from lapse to relapse (defined as seven consecutive days of smoking; yes or no)?
|
3 months after end-of-treatment
|
Cessation milestones as determined by the Timeline Followback Interview
Time Frame: 6 months after end-of-treatment
|
1) latency to lapse (number of days to the first cigarette after the quit day); 2) was there a progression from lapse to relapse (defined as seven consecutive days of smoking; yes or no)?
|
6 months after end-of-treatment
|
Physical tobacco dependence
Time Frame: 1 month after end-of-treatment
|
Tobacco dependence as measured by the Fagerstrom Test of Cigarette Dependence (FTCD).
The FTCD is a widely used 9-item measure of physical dependence.
FTCD scores, computed from the sum of the items, range from 0 to 10, with greater scores indicating greater dependence.
|
1 month after end-of-treatment
|
Physical tobacco dependence
Time Frame: 3 months after end-of-treatment
|
Tobacco dependence as measured by the Fagerstrom Test of Cigarette Dependence (FTCD).
The FTCD is a widely used 9-item measure of physical dependence.
FTCD scores, computed from the sum of the items, range from 0 to 10, with greater scores indicating greater dependence.
|
3 months after end-of-treatment
|
Physical tobacco dependence
Time Frame: 6 months after end-of-treatment
|
Tobacco dependence as measured by the Fagerstrom Test of Cigarette Dependence (FTCD).
The FTCD is a widely used 9-item measure of physical dependence.
FTCD scores, computed from the sum of the items, range from 0 to 10, with greater scores indicating greater dependence.
|
6 months after end-of-treatment
|
Motivational tobacco dependence
Time Frame: 1 month after end-of-treatment
|
Tobacco dependence as measured by the and the Wisconsin Inventory of Smoking Dependence Motives (WISDM) questionnaire.
The WISDM-68 is a 68-item measure designed to assess dependence as a motivational state on 13 subscales: Affiliative Attachment, Automaticity, Loss of Control, Behavioral Choice, Cognitive Enhancement, Craving, Cue Exposure, Negative Reinforcement, Positive Reinforcement, Social and Environmental Goads, Taste and Sensory Properties, Tolerance, and Weight Control.
Scores on each subscale, computed from the mean of their respective items, range from 1 to 7, with greater scores indicating greater dependence.
|
1 month after end-of-treatment
|
Motivational tobacco dependence
Time Frame: 3 months after end-of-treatment
|
Tobacco dependence as measured by the and the Wisconsin Inventory of Smoking Dependence Motives (WISDM) questionnaire.
The WISDM-68 is a 68-item measure designed to assess dependence as a motivational state on 13 subscales: Affiliative Attachment, Automaticity, Loss of Control, Behavioral Choice, Cognitive Enhancement, Craving, Cue Exposure, Negative Reinforcement, Positive Reinforcement, Social and Environmental Goads, Taste and Sensory Properties, Tolerance, and Weight Control.
Scores on each subscale, computed from the mean of their respective items, range from 1 to 7, with greater scores indicating greater dependence.
|
3 months after end-of-treatment
|
Motivational tobacco dependence
Time Frame: 6 months after end-of-treatment
|
Tobacco dependence as measured by the and the Wisconsin Inventory of Smoking Dependence Motives (WISDM) questionnaire.
The WISDM-68 is a 68-item measure designed to assess dependence as a motivational state on 13 subscales: Affiliative Attachment, Automaticity, Loss of Control, Behavioral Choice, Cognitive Enhancement, Craving, Cue Exposure, Negative Reinforcement, Positive Reinforcement, Social and Environmental Goads, Taste and Sensory Properties, Tolerance, and Weight Control.
Scores on each subscale, computed from the mean of their respective items, range from 1 to 7, with greater scores indicating greater dependence.
|
6 months after end-of-treatment
|
Withdrawal symptoms
Time Frame: 1 month after end-of-treatment
|
Withdrawal symptoms as measured by the 28-item Wisconsin Smoking Withdrawal Scale (WSWS).
The WSWS measures smoking withdrawal symptoms on 7 subscales: Anger, Anxiety, Concentration, Craving, Hunger, Sadness, and Sleep Difficulty.
Scores on each subscale, computed from the mean of their respective items, range from 0 to 4, with greater scores indicating greater withdrawal.
|
1 month after end-of-treatment
|
Withdrawal symptoms
Time Frame: 3 months after end-of-treatment
|
Withdrawal symptoms as measured by the 28-item Wisconsin Smoking Withdrawal Scale (WSWS).
The WSWS measures smoking withdrawal symptoms on 7 subscales: Anger, Anxiety, Concentration, Craving, Hunger, Sadness, and Sleep Difficulty.
Scores on each subscale, computed from the mean of their respective items, range from 0 to 4, with greater scores indicating greater withdrawal.
|
3 months after end-of-treatment
|
Withdrawal symptoms
Time Frame: 6 months after end-of-treatment
|
Withdrawal symptoms as measured by the 28-item Wisconsin Smoking Withdrawal Scale (WSWS).
The WSWS measures smoking withdrawal symptoms on 7 subscales: Anger, Anxiety, Concentration, Craving, Hunger, Sadness, and Sleep Difficulty.
Scores on each subscale, computed from the mean of their respective items, range from 0 to 4, with greater scores indicating greater withdrawal.
|
6 months after end-of-treatment
|
Abstinence-related expectancies
Time Frame: 1 month after end-of-treatment
|
Abstinence-related expectancies as measured by the 55-items Smoking Abstinence Questionnaire (SAQ).
The SAQ measures expectancies for abstinence from smoking on 10 subscales: Withdrawal, Social Improvement/Non-smoker Identity, Adverse Outcomes, Treatment Effectiveness, Common Reasons, Barriers to Treatment, Social Support, Optimistic Outcomes, Coffee Use, and Weight Gain.
Scores on each subscale, computed from the mean of their respective items, range from 0 to 6, with greater scores reflecting stronger expectancies.
|
1 month after end-of-treatment
|
Abstinence-related expectancies
Time Frame: 3 months after end-of-treatment
|
Abstinence-related expectancies as measured by the 55-item Smoking Abstinence Questionnaire (SAQ).
The SAQ measures expectancies for abstinence from smoking on 10 subscales: Withdrawal, Social Improvement/Non-smoker Identity, Adverse Outcomes, Treatment Effectiveness, Common Reasons, Barriers to Treatment, Social Support, Optimistic Outcomes, Coffee Use, and Weight Gain.
Scores on each subscale, computed from the mean of their respective items, range from 0 to 6, with greater scores reflecting stronger expectancies.
|
3 months after end-of-treatment
|
Abstinence-related expectancies
Time Frame: 6 months after end-of-treatment
|
Abstinence-related expectancies as measured by the 55-item Smoking Abstinence Questionnaire (SAQ).
The SAQ measures expectancies for abstinence from smoking on 10 subscales: Withdrawal, Social Improvement/Non-smoker Identity, Adverse Outcomes, Treatment Effectiveness, Common Reasons, Barriers to Treatment, Social Support, Optimistic Outcomes, Coffee Use, and Weight Gain.
Scores on each subscale, computed from the mean of their respective items, range from 0 to 6, with greater scores reflecting stronger expectancies.
|
6 months after end-of-treatment
|
Thoughts about abstinence
Time Frame: 1 month after end-of-treatment
|
Motivation to quit, expected difficulty quitting, and confidence in one's ability to quit are measured by one item each by the Thoughts About Abstinence (TAA) questionnaire.
Scores on each item range from 1 to 10, with greater scores indicating greater motivation to quit, expected difficulty quitting, and confidence in one's ability to quit, respectively.
|
1 month after end-of-treatment
|
Thoughts about abstinence
Time Frame: 3 months after end-of-treatment
|
Motivation to quit, expected difficulty quitting, and confidence in one's ability to quit are measured by one item each by the Thoughts About Abstinence (TAA) questionnaire.
Scores on each item range from 1 to 10, with greater scores indicating greater motivation to quit, expected difficulty quitting, and confidence in one's ability to quit, respectively.
|
3 months after end-of-treatment
|
Thoughts about abstinence
Time Frame: 6 months after end-of-treatment
|
Motivation to quit, expected difficulty quitting, and confidence in one's ability to quit are measured by one item each by the Thoughts About Abstinence (TAA) questionnaire.
Scores on each item range from 1 to 10, with greater scores indicating greater motivation to quit, expected difficulty quitting, and confidence in one's ability to quit, respectively.
|
6 months after end-of-treatment
|
Intolerance for smoking abstinence discomfort
Time Frame: 1 month after end-of-treatment
|
Intolerance for smoking abstinence discomfort, as measured by the 17-tem Intolerance for Smoking Abstinence Discomfort Questionnaire (IDQ-S).
The IDQ-S assesses the inability to tolerate smoking abstinence discomfort on two subscales: Withdrawal Intolerance and Lack of Cognitive Coping.
Scores on each subscale, computed from the mean of their respective items, range from 1 to 5, with greater scores indicating greater inability to tolerate abstinence.
|
1 month after end-of-treatment
|
Intolerance for smoking abstinence discomfort
Time Frame: 3 months after end-of-treatment
|
Intolerance for smoking abstinence discomfort, as measured by the 17-item Intolerance for Smoking Abstinence Discomfort Questionnaire (IDQ-S).
The IDQ-S assesses the inability to tolerate smoking abstinence discomfort on two subscales: Withdrawal Intolerance and Lack of Cognitive Coping.
Scores on each subscale, computed from the mean of their respective items, range from 1 to 5, with greater scores indicating greater inability to tolerate abstinence.
|
3 months after end-of-treatment
|
Intolerance for smoking abstinence discomfort
Time Frame: 6 months after end-of-treatment
|
Intolerance for smoking abstinence discomfort, as measured by the 17-item Intolerance for Smoking Abstinence Discomfort Questionnaire (IDQ-S).
The IDQ-S assesses the inability to tolerate smoking abstinence discomfort on two subscales: Withdrawal Intolerance and Lack of Cognitive Coping.
Scores on each subscale, computed from the mean of their respective items, range from 1 to 5, with greater scores indicating greater inability to tolerate abstinence.
|
6 months after end-of-treatment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 1, 2019
Primary Completion (Estimated)
March 1, 2024
Study Completion (Estimated)
June 24, 2024
Study Registration Dates
First Submitted
April 5, 2019
First Submitted That Met QC Criteria
April 9, 2019
First Posted (Actual)
April 11, 2019
Study Record Updates
Last Update Posted (Estimated)
December 11, 2023
Last Update Submitted That Met QC Criteria
December 7, 2023
Last Verified
December 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 000522656
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tobacco Dependence
-
Washington University School of MedicineNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedSmoking | Smoking Cessation | Tobacco Use | Tobacco Smoking | Tobacco Use Cessation | Nicotine Dependence | Tobacco Dependence | Smoking, Tobacco | Nicotine Use Disorder | Nicotine Dependence, Cigarettes | Smoking, Cigarette | Nicotine Dependence Tobacco Product | Tobacco; Use, Rehabilitation | Smoking (Tobacco) Addiction and other conditionsUnited States
-
Juul Labs, Inc.Rose Research Center, LLCCompletedTobacco Use | Tobacco Smoking | Nicotine Dependence, Other Tobacco ProductUnited States
-
Juul Labs, Inc.CelerionCompletedTobacco Use | Smoking, Tobacco | Nicotine Dependence, Other Tobacco ProductUnited States
-
University of Nevada, RenoNot yet recruitingTobacco Dependence Caused by CigarettesUnited States
-
Centro Hospitalar Lisboa OcidentalCompleted
-
Juul Labs, Inc.CompletedTobacco Use | Tobacco Smoking | Nicotine Dependence | Nicotine Dependence, CigarettesNew Zealand
-
Medical University InnsbruckCompletedSubstance Abuse | Nicotine Dependence | Tobacco Dependence | Substance DependenceAustria
-
Juul Labs, Inc.CompletedTobacco Use | Tobacco Smoking | Nicotine Dependence | Nicotine Dependence, CigarettesNew Zealand
-
Assistance Publique - Hôpitaux de ParisRecruitingAdults (Male and Female Subjects) With Tobacco DependenceFrance
-
University of Wisconsin, MadisonCompleted
Clinical Trials on cognitive-behavioral withdrawal regulation strategies
-
University of CyprusUnknown
-
University of Alabama at BirminghamCompletedSmoking CessationUnited States
-
Pennington Biomedical Research CenterThe Coca-Cola CompanyCompletedParent-targeted Mobile Phone Based Intervention to Increase Physical Activity in Children (P-Mobile)Physical ActivityUnited States
-
The Miriam HospitalCompleted
-
Philipps University Marburg Medical CenterUnknownSomatic Symptom Disorder (DSM-5)Germany
-
Philipps University Marburg Medical CenterGerman Research Foundation; University of Giessen; Universitätsklinikum Hamburg-Eppendorf and other collaboratorsCompletedSomatic Symptom Disorder (DSM-V)Germany
-
National Institute of Diabetes and Digestive and...Virginia Commonwealth University; Children's National Research InstituteCompleted
-
University of North Carolina, Chapel HillNational Institute of Mental Health (NIMH)Recruiting
-
Phoenix VA Health Care SystemCompletedChronic PainUnited States
-
Royal Perth HospitalRoyal Perth Hospital Medical Research FoundationCompleted